Ocular toxicity related to cetuximab monotherapy in patients with colorectal cancer

Clinical Colorectal Cancer

Volumn 6, Issue 3, 2006, Pages 224-225

  Dranko, Shelley ^a   Kinney, Connie ^a   Ramanathan, Ramesh K ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Blepharitis; Epidermal growth factor receptor; Erythema; Itchiness; Tearing; Trichomegaly

Indexed keywords

CETUXIMAB; GENTAMICIN;

AGED; ARTICLE; BLEPHARITIS; BLURRED VISION; CASE REPORT; COLORECTAL CANCER; CONJUNCTIVITIS; DISEASE COURSE; DISEASE SEVERITY; DRUG WITHDRAWAL; EYE DISCOMFORT; EYE IRRITATION; EYE TOXICITY; EYELID ERYTHEMA; EYELID PRURITUS; FEMALE; HUMAN; LACRIMATION; LACRIMATION DISORDER; MALE; METASTASIS; MONOTHERAPY; MULTIPLE DRUG DOSE; OCULAR PRURITUS; PHYSICAL EXAMINATION; TREATMENT OUTCOME;

EID: 33750199017     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2006.n.040     Document Type: Article

References (8)

1. Tonini G, Vincenzi B, Santini D, et al. Ocular toxicity related to cetuximab monotherapy in an advanced colorectal cancer patient. J Natl Cancer Inst 2005; 97:606-607.
2. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16:1425-1433.
3. Erbitux™ [package insert]. New York, NY: ImClone Systems Inc; 2004. Available at: http://www.fda.gov/cder/foi/label/2004/125084lbl.pdf.
4. Gustafson NF, Saltz L, Cunningham D, et al. Safety profile of cetuximab in patients with metastatic colorectal cancer. Presented at: American Society of Clinical Oncology 2004 Gastrointestinal Cancers Symposium; January 2004; San Francisco, CA. Abstract #237.
5. Saltz L, Meropol N, Loehrer P, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201-1208.
6. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-345.
7. Bouche O, Brixi-Benmansour H, Bertin A, et al. Trichomegaly of the eyelashes following treatment with cetuximab. Ann Oncol 2005; 16:1711-1712.
8. Carter S. Eyelid disorders: diagnosis and management. Am Fam Physician 1998; 57:2695.